Company cases
Guidance for 2022/23 maintained despite disappointing H1 22/23 from cannabis healthcare company CS Medica
Despite a revenue in H1 22/23 of DKK 0.3 million (DKK 0.2 million) CS Medica maintains the expectation for the
17. May 2023
We have decades of experience in analyzing small and mid-cap stocks as well as disseminating this information to retail investors. With investment cases, we provide free information on investment opportunities within the segment of Nordic small and mid-caps companies for primarily a Nordic investing audience.
If you want to contact us directly, find contact details for the individual employee under Line Up.
Despite a revenue in H1 22/23 of DKK 0.3 million (DKK 0.2 million) CS Medica maintains the expectation for the
After the arrival of ChatGPT, artificial intelligence has once again become the talk of the town and has triggered major
Ekobot’s Q1 2023 report was as expected and the investment case with focus on further sales and commercialization of the
Curasight and Curium of France have entered into a partnership agreement for uTRACE for prostate cancer. This has triggered a
Danish Biotech Weekly with insights to listed Danish biotech companies. We keep you updated on their news flow including updates
Last week saw no major changes at index level, with the Nordic growth exchanges unchanged. However, there are always opportunities
Nexcom maintains a revenue in the level of DKK 11-15 million and EBITDA in the level of (2) – 1.5
Last week, the Nordic growth stock markets fell, while the major indices continued their price increases in 2023. The week’s
Kapital Partner performs or has within the last 12 months performed corporate finance, market relations, investor relations, Certified Adviser or other advisory activities for the following listed companies: NORD.investments, Biosergen, InterMail, Pila Pharma, Hypefactors, Curasight, Evaxion, Re-Match, Audientes, Mdundo.com, Nexcom.
Del indlægget på sociale media eller på email.